Cytoplasm-localized SIRT1 downregulation attenuates apoptosis and cell cycle arrest in cisplatin-resistant lung...

Area of Science:

• Cell Biology
• Molecular Oncology
• Biochemistry

Background:

• Lung cancer drug resistance remains a significant clinical challenge.
• Sirtuins (SIRTs) are NAD+-dependent deacetylases involved in various cellular processes.
• Sirtuin-1 (SIRT1) role in cancer drug resistance is complex and warrants further investigation.

Purpose of the Study:

• To investigate the role of SIRT1 in cisplatin resistance in A549 lung cancer cells.
• To elucidate the mechanism by which SIRT1 influences cell survival and apoptosis in the context of drug resistance.
• To explore potential therapeutic strategies targeting SIRT1 for overcoming cisplatin resistance.

Main Methods:

• Western blot and RT-PCR to assess SIRT1 expression.
• MTT assay, ECIS, and FACS analysis to evaluate cytotoxicity, proliferation, and cell cycle distribution.
• Transfection studies, immunofluorescence, immunoprecipitation, and proteasome activity assays to determine SIRT1 function and interactions.

Main Results:

• Cisplatin-resistant A549/CADD cells showed decreased SIRT1 expression and mesenchymal characteristics.
• SIRT1 depletion was linked to cell cycle arrest and altered p53 stability via ubiquitination.
• Cisplatin treatment reduced cytoplasmic SIRT1 levels and increased proteasomal activity in resistant cells.

Conclusions:

• SIRT1 is downregulated in cisplatin-resistant A549 cells, contributing to drug resistance.
• The mechanism involves SIRT1's regulation of p53 stability and proteasomal degradation.
• Targeting SIRT1 depletion and associated pathways presents a potential strategy to overcome lung cancer drug resistance.